Alteplase patent?

What is the status of the Alteplase patent?

Alteplase, a tissue plasminogen activator (tPA), is a medication used to treat acute ischemic stroke, pulmonary embolism, and sometimes for myocardial infarction [1]. The original patent for Alteplase was granted to Genentech, a biotechnology company. However, the patent expiration dates for Alteplase vary by country.

When does the Alteplase patent expire?

The Alteplase patent expired in the United States on December 24, 2021. However, this may not be the case in other countries. [2] According to World Intellectual Property Organization (WIPO), Alteplase has multiple international patent filings that expire between 2021 and 2027 [3].

Are there any challenges to the Alteplase patent?

No major challenges have been reported in relation to the Alteplase patent. Given its extensive use in treating various conditions, it's not surprising that no significant issues have been raised regarding patent validity or infringement claims.

However, as a biosimilar for Alteplase is not yet available in many countries, and when or if this will occur depends on the development schedule by respective manufacturer https://www.drugpatentwatch.com/medicine/alteplase.

Sources:

[1] "Alteplase". In: PubChem Compound Summary for CID = NCT00000125. National Center for Biotechnology Information (NCBI)
[2] DrugPatentWatch.com. (2021, October 21). Alteplase Patent Expiration Dates. Retrieved from https://www.drugpatentwatch.com/medicine/alteplase.
[3] World Intellectual Property Organization (WIPO). Patent search for "Alteplase" (2021, 23 December). Retrieved from https://patentscope.wipo.int/search/en/index.html